Physicochemical Properties
| Molecular Formula | C25H26O6 |
| Molecular Weight | 422.47 |
| Exact Mass | 422.172 |
| CAS # | 161068-53-7 |
| PubChem CID | 21147600 |
| Appearance | Light yellow to yellow solid powder |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 665.9±55.0 °C at 760 mmHg |
| Flash Point | 228.2±25.0 °C |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.650 |
| LogP | 6.59 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 31 |
| Complexity | 745 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | QLZMBCVLWOJASJ-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C25H26O6/c1-13(2)5-7-15-9-16(10-21(29)24(15)30)22-12-20(28)23-19(27)11-18(26)17(25(23)31-22)8-6-14(3)4/h5-6,9-12,26-27,29-30H,7-8H2,1-4H3 |
| Chemical Name | 2-[3,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-8-(3-methylbut-2-enyl)chromen-4-one |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Compound 6, epimedokoreanin B, exhibited noteworthy suppression of lung cancer cell growth (A549, Calu1, and H1299) over a 48-hour period at 3.13–25 μM. Human bronchial epithelial cells BEAS-2B are not harmed by epimedokoreanin B [1]. Treatment with epimedokoreanin B decreased the migration and proliferation of A549 and NCI-H292 cells, which was accompanied with cytoplasmic vacuolation. Epimedokoreanin B-treated cells showed autophagosome accumulation together with autophagic flux obstruction, which is consistent with endoplasmic reticulum stress [2]. In human monocyte-derived macrophages (HMDM), Epimedokoreanin B (5 μM; 24 hours) reduces the production of IL-10, a known M2 marker, and CD163 expression, suggesting that it prevents M2 polarization. STAT3 activity in HMDMs is inhibited by epimedokoreanin B [4]. |
| ln Vivo | In the LM8 tumor-bearing mouse model, epimedokoreanin B (20 mg/kg; oral; three times per week; for 17 days) suppresses tumor growth [4]. |
| Cell Assay |
Cell Cytotoxicity Assay[1] Cell Types: A549, Calu1 and H1299 cells Tested Concentrations: 3.13 μM, 6.25 μM, 12.5 μM and 25.0 μM Incubation Duration: 48 hrs (hours) Experimental Results: demonstrated significate inhibitory effect on proliferation against lung cancer cell A549, Calu1 and H1299. Western Blot Analysis[4] Cell Types: Human monocyte-derived macrophages (HMDMs) Tested Concentrations: 5 μM Incubation Duration: 24 hrs (hours) Experimental Results: Dramatically suppressed IL-10-induced JAK1/STAT3 activation.and H1299. |
| Animal Protocol |
Animal/Disease Models: Female C3H mice (8-10 weeks old) injected with LM8 cells[4] Doses: 20 mg/kg Route of Administration: Oral administration; thrice a week; for 17 days Experimental Results: Inhibited tumor growth. |
| References |
[1]. Flavonoids from the leaves of Epimedium Koreanum Nakai and their potential cytotoxic activities. Nat Prod Res. 2020 May;34(9):1256-1263. [2]. Epimedokoreanin B inhibits the growth of lung cancer cells through endoplasmic reticulum stress-mediated paraptosis accompanied by autophagosome accumulation. Chem Biol Interact. 2022 Oct 1;366:110125. [3]. Inhibition of gingipains and Porphyromonas gingivalis growth and biofilm formation by prenyl flavonoids. J Periodontal Res. 2017 Feb;52(1):89-96. [4]. Flavonoid Compounds Contained in Epimedii Herba Inhibit Tumor Progression by Suppressing STAT3 Activation in the Tumor Microenvironment. Front Pharmacol. 2020 Mar 18;11:262. |
Solubility Data
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3670 mL | 11.8352 mL | 23.6703 mL | |
| 5 mM | 0.4734 mL | 2.3670 mL | 4.7341 mL | |
| 10 mM | 0.2367 mL | 1.1835 mL | 2.3670 mL |